Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Thailand Consensus on Helicobacter pylori Treatment 2015

  • Published : 2016.05.01
⟨ Previous Next ⟩

Abstract

Management of Helicobacter pylori infection is an important aspect of many upper gastrointestinal tract diseases, such as chronic gastritis, peptic ulcer disease, gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. The Thailand Consensus on H. pylori treatment 2015 consisted of 22 national experts who took active roles, discussed all important clinical information and investigated clinical aspects in four workshops, focuising on: (1) Diagnosis (2) Treatment (3) Follow-up after eradication and (4) H. pylori infection and special conditions. Experts were invited to participate on the basis of their expertise and contribution to H. pylori works and/or consensus methodology. The results of each workshop were taken to a final consensus vote by all experts. Recommendations were developed from the best evidence and availability to guide clinicians in management of this specific infection associated with variety of clinical outcomes.

Keywords

References

  1. Abraham NS, Hlatky MA, Antman EM, et al (2010). ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol, 105, 2533-49. https://doi.org/10.1038/ajg.2010.445
  2. Alahdab YO, Kalayci C (2014). Helicobacter pylori : Management in 2013. World J Gastroenterol, 20, 5302-7. https://doi.org/10.3748/wjg.v20.i18.5302
  3. Arkkila PE, Seppala K, Kosunen TU, et al (2005). Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers. Eur J Gastroenterol Hepatol, 17, 93-101. https://doi.org/10.1097/00042737-200501000-00018
  4. Asaka M, Kato M, Graham DY (2010). Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med, 49, 633-6. https://doi.org/10.2169/internalmedicine.49.3470
  5. Asaka M, Sugiyama T, Nobuta A, et al (2001). Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter, 6, 294-9. https://doi.org/10.1046/j.1523-5378.2001.00042.x
  6. Bravo LE, Realpe JL, Campo C, et al (1999). Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol, 94, 2380-3. https://doi.org/10.1111/j.1572-0241.1999.01361.x
  7. Burucoa C, Delchier JC, Courillon-Mallet A, et al (2013). Comparative evaluation of 29 commercial Helicobacter pylori serological kits. Helicobacter, 18, 169-79. https://doi.org/10.1111/hel.12030
  8. Cammarota G, Martino A, Pirozza G, et al (2004). High efficacy of 1-week doxycyline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for H. pylori infection. Aliment Pharmacol Ther, 19, 789-95. https://doi.org/10.1111/j.1365-2036.2004.01910.x
  9. Chan FK, Ching JY, Suen BY, et al (2013). Effects of Helicobacter pylori infection on long-term risk of peptic ulcer bleeding in low-dose aspirin users. Gastroenterol, 144, 528-35. https://doi.org/10.1053/j.gastro.2012.12.038
  10. Chan FK, Sung JJ, Chung SC, et al (1997). Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet, 350, 975-9. https://doi.org/10.1016/S0140-6736(97)04523-6
  11. Chan FK, To KF, Wu JC, et al (2002). Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet, 359, 9-13. https://doi.org/10.1016/S0140-6736(02)07272-0
  12. Chen HN, Wang Z, Li X et al (2016). Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis. Gastric Cancer.
  13. Chen LT, Lin JT, Tai JJ, et al (2005). Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst, 97, 1345-53. https://doi.org/10.1093/jnci/dji277
  14. Chey WD, Wong BC (2007). Practice parameters committee of the american college of gastroenterology. american college of gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol, 102, 1808. https://doi.org/10.1111/j.1572-0241.2007.01393.x
  15. Chitapanarux T, Thongsawat S, et al (2015). Effect of Bifidobacterium longum on-based triple PPI therapy for eradication of Helicobacter pylori. Functional Foods, 13, 289-94. https://doi.org/10.1016/j.jff.2015.01.003
  16. Chung JW, Lee JH, Jung HY, et al (2011). Second-line Helicobacter pylori eradication: a randomized comparison of 1 week or 2 week bismuth-containing quadruple therapy. Helicobacter, 16, 289-94. https://doi.org/10.1111/j.1523-5378.2011.00844.x
  17. Chung SJ, Lim SH, Choi J, et al (2011). Helicobacter pylori serology inversely correlated with the risk and severity of reflux esophagitis in Helicobacter pylori endemic Area: A matched case-control study of 5,616 health check-up Koreans. J Neurogastroenterol Motil, 17, 267-73. https://doi.org/10.5056/jnm.2011.17.3.267
  18. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 52, 6735-40.
  19. Correa P, Piazuelo MB, Wilson KT (2010). Pathology of gastric intestinal metaplasia: clinical implications. Am J Gastroenterol, 105, 493-8. https://doi.org/10.1038/ajg.2009.728
  20. Crowe SE (2015). Indications and diagnostic tests for Helicobacter pylori infection. Up To Date. Literature review current through: Jul 2015. | This topic last updated: Mar 12, 2015.
  21. Cutler AF, Elnagger M, Brooks E, et al (1998). Effect of standard and high dose ranitidine on [13C] urea breath test results. Am J Gastroenterol, 93, 1297-99. https://doi.org/10.1111/j.1572-0241.1998.00412.x
  22. Cutler AF, Prasad VM, Santogade P (1998). Four-year trends in Helicobacter pylori IgG serology following successful eradication. Am J Med, 105, 18. https://doi.org/10.1016/S0002-9343(98)00134-X
  23. de Vries AC, van Grieken NC, Looman CW, et al (2008). Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterol, 134, 945-52. https://doi.org/10.1053/j.gastro.2008.01.071
  24. Di Caro S, Fini L, Daoud Y, et al (2012). Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second line: a systematic review. World J Gastroenterol, 18, 5669-78. https://doi.org/10.3748/wjg.v18.i40.5669
  25. Dinis-Ribeiro M, Areia M, de Vries AC et al (2012). Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy, 44, 74-94. https://doi.org/10.1055/s-0031-1291491
  26. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, et al (2004). A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol, 57, 177-82. https://doi.org/10.1136/jcp.2003.11270
  27. Federico A, Nardone G, Gravina AG, et al (2012). Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection. Gastroenterol, 143, 55-61. https://doi.org/10.1053/j.gastro.2012.03.043
  28. Fischbach L, Evans EL (2007). Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther, 26, 343-57. https://doi.org/10.1111/j.1365-2036.2007.03386.x
  29. Fischbach LA, Graham DY, Kramer JR, et al (2014). Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol, 109, 357-68. https://doi.org/10.1038/ajg.2013.443
  30. Figura N, Crabtree JE, Dattilo M (1997). In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother, 39, 585-90. https://doi.org/10.1093/jac/39.5.585
  31. Ford AC, Delaney BC, Forman D, et al (2004). Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol, 99, 1833-55. https://doi.org/10.1111/j.1572-0241.2004.40014.x
  32. Ford AC, Delaney BC, Forman D, et al (2006). Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev.
  33. Ford AC, Forman D, Hunt RH, et al (2014). Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ, 348, 3174. https://doi.org/10.1136/bmj.g3174
  34. Franceschi FL, Cazzato A, et al (2007). A Role of probiotics in patients with Helicobacter pylori infection. Helicobacter, 12, 59-63. https://doi.org/10.1111/j.1523-5378.2007.00565.x
  35. Fuccio L, Zagari RM, Eusebi LH, et al (2009). Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med, 151, 121-8. https://doi.org/10.7326/0003-4819-151-2-200907210-00009
  36. Fukase K, Kato M, Kikuchi S, et al (2008). Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet, 372, 392-7. https://doi.org/10.1016/S0140-6736(08)61159-9
  37. Gatta L, Vakil N, Ricci C, et al (2004). Effect of proton pump inhibitors and antacid therapy on 13C-urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol, 99, 823-9. https://doi.org/10.1111/j.1572-0241.2004.30162.x
  38. Gisbert JP, Barrio J, Modolell I, et al (2015). Helicobacter pylori first-line and rescue treatment in the presence of penicillin allergy. Dig Dis Sci, 60, 458-64. https://doi.org/10.1007/s10620-014-3365-2
  39. Gisbert JP, Khorrami S, Carballo F, et al (2004). H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 4062.
  40. Gisbert JP, Gisbert JL, Marcos S, et al (2005). Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin. Aliment Pharmacol Ther, 22, 1041-6. https://doi.org/10.1111/j.1365-2036.2005.02687.x
  41. Gisbert JP, Pajares JM (2005). Review article: C-urea breath test in the management of Helicobacter pylori infection: Review article. Diagnosis Liver Disease, 37, 899-906. https://doi.org/10.1016/j.dld.2005.09.006
  42. Gisbert JP, Pajares JM (2005). Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther, 21, 795-804. https://doi.org/10.1111/j.1365-2036.2005.02418.x
  43. Goddard AF, Badreldin R, Pritchard DM et al (2010). The management of gastric polyps. Gut, 59, 1270-6. https://doi.org/10.1136/gut.2009.182089
  44. Graham DY, Hammoud F, El-Zimaity HM, et al (2003). Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther, 17, 1229-36. https://doi.org/10.1046/j.1365-2036.2003.01583.x
  45. Graham DY, Klein PD (2000). Accurate diagnosis of Helicobacter pylori. 13C-urea breath test. Gastroenterol Clin North Am, 29, 885-93. https://doi.org/10.1016/S0889-8553(05)70156-4
  46. Graham DY, Opekun AR, Hammoud F, et al (2003). Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol, 98, 1005-9. https://doi.org/10.1111/j.1572-0241.2003.07426.x
  47. Hackelsberger A, Schultze V, Gunther T, et al (1997). Helicobacter pylori prevalence in reflux esophagitis: A case control study (abstract). Gastroenterol, 112, A137.
  48. Higuchi K, Fujiwara Y, Tominaga K, et al (2003). Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther, 17, 111-17.
  49. Howden CW, Hunt RH (1998). Guidelines for the management of Helicobacter pylori infection. ad hoc committee on practice parameters of the american college of gastroenterology. Am J Gastroenterol, 93, 2330-8. https://doi.org/10.1111/j.1572-0241.1998.00684.x
  50. Hong SS, Jung HY, Choi KD, et al (2006). A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication. Helicobacter, 11, 569-73. https://doi.org/10.1111/j.1523-5378.2006.00460.x
  51. Huang JQ, Sridhar S, Hunt RH (2002). Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet, 359, 14-22. https://doi.org/10.1016/S0140-6736(02)07273-2
  52. Jainan W, Vilaichone RK (2014). Effects of the CYP2C19 genetic polymorphism on gastritis, peptic ulcer disease, peptic ulcer bleeding and gastric cancer. Asian Pac J Cancer Prev, 15, 10957-60.
  53. Jeajaroonwong W (2003). PPI-based Triple Therapy for Helicobacter pylori Eradication at NaKhonpathom Hospital. Reg 4-5 Med J, 31, 14-8.
  54. Jyotheeswaran S, Shah AN, Jin HO, et al (1998). Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol, 93, 574. https://doi.org/10.1111/j.1572-0241.1998.167_b.x
  55. Kanizaj TF, Kunac N (2014). Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol, 20, 699-705. https://doi.org/10.3748/wjg.v20.i3.699
  56. Kato M, Asaka M, Ono S, et al (2007). Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection. J Gastroenterol, 42, 16-20.
  57. Kim SG, Jung HK, Lee HL, et al (2014). Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol, 29, 1371-86. https://doi.org/10.1111/jgh.12607
  58. Kongchayanun C, Vilaichone R, Pornthisarn B, et al (2012). Pilot studies to identify the optimum duration of concomitant helicobacter pylori eradication therapy in Thailand. Helicobacter, 17, 282-5. https://doi.org/10.1111/j.1523-5378.2012.00953.x
  59. Kullavanijaya P, Thong-Ngam D, Hanvivatvong O, et al (2004). Analysis of eight different methods for the detection of Helicobacter pylori infection in patients with dyspepsia. J Gastroenterol Hepatol, 19, 1392-6. https://doi.org/10.1111/j.1440-1746.2004.03506.x
  60. Laine L, Estrada R, Trujillo M, et al (1998). Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med, 129, 547. https://doi.org/10.7326/0003-4819-129-7-199810010-00007
  61. Laine L, Hopkins RJ, Girardi LS (1998). Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol, 93, 1409.
  62. Lamouliatte H, Megraud F, Delchier J, et al (2003). Second-line treatment for failure toeradicate H. pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther, 18, 791-7. https://doi.org/10.1046/j.1365-2036.2003.01759.x
  63. Lam SK, Ching CK, Lai KC, et al (1997). Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomized double blind placebo controlled study. Gut, 41, 43. https://doi.org/10.1136/gut.41.1.43
  64. Leodoltor A, Dominguez-Munoz JE, von Arnim U, et al (1999). Validity of a modified 13 C-urea breath test for pre-and posttreatment diagnosis of Helicobacter pylori in the routine clinical setting. Am J Gastroenterol, 94, 2100-4. https://doi.org/10.1111/j.1572-0241.1999.01284.x
  65. Leodolter A, Kulig M, Brasch H, et al (2001). A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther, 15, 1949. https://doi.org/10.1046/j.1365-2036.2001.01109.x
  66. Leung WK, Lin SR, Ching JY et al (2004). Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut, 53, 1244-9. https://doi.org/10.1136/gut.2003.034629
  67. Loy CT, Irwig LM, Katelaris PH, et al (1996). Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol, 91, 1138-44.
  68. Lundell L, Havu N, Miettinen P, et al (2006). Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther, 23, 639-47. https://doi.org/10.1111/j.1365-2036.2006.02792.x
  69. Lundell L, Vieth M, Gibson F, et al (2015). Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther, 42, 649-63. https://doi.org/10.1111/apt.13324
  70. Mahachai V, Vilaichone RK (2011). Current status of Helicobacter pylori Infection in Thailand. Helicobacter Research, 15, 38-44.
  71. Maehata Y, Nakamura S, Fujisawa K, et al (2012). Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc, 75, 39-46. https://doi.org/10.1016/j.gie.2011.08.030
  72. Malfertheiner P, Megraud F, O'Morain CA, et al (2012). Management of Helicobacter pylori infection--the maastricht iv/ florence consensus report. Gut, 61, 646-64. https://doi.org/10.1136/gutjnl-2012-302084
  73. Marzio L, Cellini L, Angelucci D (2003). Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. Dig Liver Dis, 35, 20e3.
  74. Moayyedi P (2011). Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". Arch Intern Med, 171, 1936-7. https://doi.org/10.1001/archinternmed.2011.541
  75. Moayyedi P, Soo S, Deeks J, et al (2000). Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. Dyspepsia Review Group. BMJ, 321, 659-64. https://doi.org/10.1136/bmj.321.7262.659
  76. Moayyedi P, Wason C, Peacock R, et al (2000). Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter, 5, 2016-14.
  77. O'Connor HJ (1999). Review article: Helicobacter pylori and gastro-oesophageal reflux disease-clinical implications and management. Aliment Pharmacol Ther, 13, 117-27. https://doi.org/10.1046/j.1365-2036.1999.00460.x
  78. Patel SK, Pratap CB, Jain AK, et al (2014). Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol, 20, 12847-59. https://doi.org/10.3748/wjg.v20.i36.12847
  79. Perri F, Manes G, Neri M, et al (2002). Helicobacter pylori antigen stool test and 13C-urea breath test in patients after eradication treatments. Am J Gastroenterol, 97, 2756. https://doi.org/10.1111/j.1572-0241.2002.07065.x
  80. Pittayanon R, Vilaichone RK, Lee GH, et al (2015). Influences of duration of treatment, CYP2C19 genotyping, interleukin-1 polymorphisms and antibiotic resistant strains in Helicobacter pylori eradication rates. digestive disease week (DDW), Washinton DC, USA (Abstract).
  81. Prapitpaiboon H, Mahachai V, Vilaichone RK (2015). High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pac J Cancer Prev, 16, 4353-6. https://doi.org/10.7314/APJCP.2015.16.10.4353
  82. Prasertpetmanee S, Mahachai V, Vilaichone RK (2013). Improved efficacy of PPI - amoxicillin - clarithromycin triple therapy for H. pylori eradication in low clarithromycin resistance areas or for tailored therapy. Helicobacter, 18, 270-3. https://doi.org/10.1111/hel.12041
  83. Rokkas T, Sechopoulos P, Pistiolas D, et al (2010). Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol, 22, 1128-33. https://doi.org/10.1097/MEG.0b013e3283398d37
  84. Romano M, Cuomo A, Gravina AG, et al (2010). Empiric levofloxacin-containing vs clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomized trial. Gut, 59, 1465-70. https://doi.org/10.1136/gut.2010.215350
  85. Ruskone-Fourmestraux A, Fischbach W, Aleman BM, et al (2011). EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut, 60, 747-58. https://doi.org/10.1136/gut.2010.224949
  86. Savarino V, Tracci D, Dulbecco P, et al (2001). Negative effect of ranitidine on the results of urea breath test for the diagnosis of Helicobacter pylori. Am J Gastroenterol, 96, 348-52. https://doi.org/10.1111/j.1572-0241.2001.03517.x
  87. Schenk BE, Kuipers EJ, Nelis GF, et al (2000). Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut, 46, 615-21. https://doi.org/10.1136/gut.46.5.615
  88. Shirin H, Levine A, Shevah O, et al (2005). Eradication of Helicobacter pylori can be accurately confirmed 14 days after termination of triple therapy using a high-dose citric acid-based 13C urea breath test. Digestion, 71, 208-12. https://doi.org/10.1159/000087045
  89. Shirota T, Kusano M, Kawamura O, et al (1999). Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol, 34, 553-9. https://doi.org/10.1007/s005350050372
  90. Sipponen P, Helske T, Jarvinen P et al (1994). Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. Gut, 35, 1167-71. https://doi.org/10.1136/gut.35.9.1167
  91. Sirimontaporn N, Thong-Ngam D, Tumwasorn S, et al (2010). Ten-day Sequential Therapy of Helicobacter pylori infection in Thailand. Am J Gastroenterol, 105, 1071-5. https://doi.org/10.1038/ajg.2009.708
  92. Smith SM, O'Morain C, McNamara D (2014). Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance. World J Gastroenterol, 20, 9912-21. https://doi.org/10.3748/wjg.v20.i29.9912
  93. Song H, Ekheden IG, Zheng Z, et al (2015). Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ, 351, 3867.
  94. Srinarong C, Mahachai V, Vilaichone RK (2014). High efficacy of 14-day standard triple therapy plus bismuth with probiotic supplement for H. pylori eradication in low clarithromycin resistance areas. Asian Pac J Cancer Prev, 15, 9909-13. https://doi.org/10.7314/APJCP.2014.15.22.9909
  95. Stathis A, Chini C, Bertoni F, et al (2009). Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol, 20, 1086-93. https://doi.org/10.1093/annonc/mdn760
  96. Sugano K, Tack J, Kuipers EJ, et al (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64, 1353-67. https://doi.org/10.1136/gutjnl-2015-309252
  97. Tan J, Wang Y, Sun X, et al (2015). The effect of Helicobacter pylori eradication therapy on the development of gastroesophageal reflux disease. Am J Med Sci, 349, 364-71. https://doi.org/10.1097/MAJ.0000000000000429
  98. Thailand Consensus for the management of Dyspepsia and Helicobacter pylori 2010 issued by The Gastroenterology Association of Thailand, Krungthep Vechasarn publishing, Bangkok, Thailand
  99. Uemura N, Okamoto S, Yamamoto S, et al (2001). Helicobacter pylori infection and the development of gastric cancer. N Engl J Med, 345, 784-9. https://doi.org/10.1056/NEJMoa001999
  100. Vaira D, Malfertheiner P, Megraud F, et al (1999). Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet, 354, 30-3. https://doi.org/10.1016/S0140-6736(98)08103-3
  101. Vakil N, Hahn B, McSorley D (2000). Recurrent symptoms and gastroesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther, 14, 45-51. https://doi.org/10.1046/j.1365-2036.2000.00677.x
  102. van Zanten SV, van der Knoop B (2008). Gastric ulcer treatment: cure of Helicobacter pylori infection without subsequent acid-suppressive therapy: is it effective? Eur J Gastroenterol Hepatol, 20, 489-91. https://doi.org/10.1097/MEG.0b013e3282f427c8
  103. Varocha M, Sirimontaporn N, Thong-Ngam D, et al (2011). Sequential therapy in clarithromycin-sensitive and resistant Helicobacter pylori based on polymerase chain reaction molecular test. J Gastroenterol Hepatol, 26, 825-8. https://doi.org/10.1111/j.1440-1746.2011.06660.x
  104. Vilaichone RK, Mahachai V, Graham DY (2006). Helicobacter pylori: Diagnosis and management. Gastroenterol Clin North Am, 35, 229-47. https://doi.org/10.1016/j.gtc.2006.03.004
  105. Vergara M, Catalan M, Gisbert JP, et al (2005). Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther
  106. Wang C, Yuan Y, Hunt RH (2009). Helicobacter pylori infection and Barrett's esophagus: a systematic review and meta-analysis. Am J Gastroenterol, 104, 492-500. https://doi.org/10.1038/ajg.2008.37
  107. Wang J, Xu L, Shi R, et al (2011). Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis. Digestion, 83, 253-60. https://doi.org/10.1159/000280318
  108. Wilcox MH, Dent TH, Hunter JO, et al (1996). Accuracy of serology for the diagnosis of Helicobacter pylori infection-a comparison of eight kits. J Clin Pathol, 49, 373-6. https://doi.org/10.1136/jcp.49.5.373
  109. Wong BC, Lam SK, Wong WM, et al (2004). Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA, 291, 187-94. https://doi.org/10.1001/jama.291.2.187
  110. Wotherspoon AC, Doglioni C, Diss TC, et al (1993). Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342, 575-7. https://doi.org/10.1016/0140-6736(93)91409-F
  111. Zagari RM, Romano M, Ojetti V, et al (2015). Guidelines for the management of Helicobacter pylori infection in Italy: the III working group consensus report 2015. Dig Liver Dis, 47, 903-12. https://doi.org/10.1016/j.dld.2015.06.010
  112. Zhang MM, Qian W, Qin YY, et al (2015). Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol, 21, 4345-57. https://doi.org/10.3748/wjg.v21.i14.4345
  113. Zullo A, Hassan C, Andriani A, et al (2009). Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis. Am J Gastroenterol, 104, 1932-7. https://doi.org/10.1038/ajg.2009.314